THOMAS GREGORY, M.D.
Medical Oncology Physician · TYLER, TX
Individual Active NPI 1174566624
Medicare payment data Part B · 2024
| Year | Beneficiaries | Services | Submitted | Allowed | Paid |
|---|---|---|---|---|---|
| 2024 | 928 | 168,597 | $14,176,222 | $3,963,003 | $3,159,100 |
| 2023 | 994 | 188,271 | $16,182,061 | $4,421,691 | $3,513,954 |
| 2022 | 980 | 184,870 | $13,944,574 | $3,824,225 | $3,052,711 |
Top procedures (2024)
| HCPCS | Description | Services | Avg allowed | Avg paid |
|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | 16,600 | $56 | $45 |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 12,240 | $0 | $0 |
| J9263 | Injection, oxaliplatin, 0.5 mg | 12,000 | $0 | $0 |
| J1453 | Injection, fosaprepitant, 1 mg | 8,700 | $0 | $0 |
| J9267 | Injection, paclitaxel, 1 mg | 8,274 | $0 | $0 |
| J9299 | Injection, nivolumab, 1 mg | 8,260 | $31 | $25 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 7,525 | $0 | $0 |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | 7,380 | $49 | $39 |
| J1756 | Injection, iron sucrose, 1 mg | 6,500 | $0 | $0 |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 4,710 | $3 | $2 |
| J1568 | Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 4,680 | $47 | $37 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 2,730 | $0 | $0 |
Taxonomy & licensure
| Specialty | Code | Primary | License | State |
|---|---|---|---|---|
| Medical Oncology Physician | 207RX0202X | ✓ | J7277 | TX |
Medicare eligibility
- Part B
- Yes
- DME
- Yes
- Home health
- Yes
- Power mobility
- Yes
- Hospice
- Yes
Other Medical Oncology Physician providers in Texas
- NPI 1659313559
- NPI 1194019075
- NPI 1346331063
- NPI 1497319636
- NPI 1346323888
- NPI 1447414776
- NPI 1063676245
- NPI 1730463324
Source: NPPES (public domain) and CMS Medicare Physician & Other Practitioners data. Not affiliated with CMS, NPPES, or any government agency.